yingweiwo

ADCs

ADCs

ADCs related products

Structure Cat No. Product Name CAS No. Product Description
ADC Control Human IgG1-Deruxtecan (DAR 8) V97196 ADC Control Human IgG1-Deruxtecan (DAR 8) ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that serves as an isotype control for the ADC Human IgG1-Deruxtecan, which inhibits DNA topoisomerase I.
ADC Control human IgG1-DM1 V103649 ADC Control human IgG1-DM1 ADC Control Human IgG1-DM1 is an ADC control consisting of human IgG1 kappa, isotype control, and linker-drug conjugate SMCC-DM1.
ADC Control Human IgG1-DM4 V103949 ADC Control Human IgG1-DM4 ADC Control Human IgG1-DM4 is the isotype control of ADC Human IgG1-DM4. The antibody part is Human IgG1 kappa, isotype control, and the ADC virulence molecule and linker part are SPDB-DM4.
ADC Control Human IgG1-McMMAF V104022 ADC Control Human IgG1-McMMAF ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 human IgG1 kappa, isotype control, and payload McMMAF.
ADC Control Human IgG1-SN-38 V103948 ADC Control Human IgG1-SN-38 ADC Control Human IgG1-SN-38 is an isotype control for ADC Human IgG1-SN-38.
Anti-CD22-NMS249 V94359 Anti-CD22-NMS249 Anti-CD22-NMS249 is a CD22-targeting antibody-drug conjugate (ADC) composed of the humanized anti-CD22 antibody Pinatuzumab, a cleavable linker (Mc-VC-PAB), and a DNA topoisomerase II inhibitor.
BL-B01D1 V103951 BL-B01D1 BL-B01D1 is a bispecific ADC that targets EGFR and HER3 through the bispecific antibody Izalontamab and inhibits DNA replication and DNA synthesis through its ADC toxin ED04, exhibiting cytotoxicity against a variety of cancer cells.
Calotatug ginistinag V104014 Calotatug ginistinag 2847102-44-5 Calotatug ginistinag (XMT-2056) is a HER2-targeting antibody-drug conjugate linked to a payload consisting of a linker (XMT-1519 conjugate-1) and a STING agonist (STING agonist-20) with potential immune-activating and anti-tumor activities.
Exatecan Intermediate 3 V78751 Exatecan Intermediate 3 Exatecan Intermediate 3 is the intermediate of Exatecan.
FZ-AD005 V94122 FZ-AD005 FZ-AD005 is a DLL3-targeted ADC containing a novel anti-DLL3 antibody, FZ-A038, and a valine-alanine (Val-Ala) dipeptide linker.
Izeltabart (IMGC-936) V76158 Izeltabart (IMGC-936) 2642078-60-0 Izeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9.
KRAS degrader-1 V53069 KRAS degrader-1 2795275-59-9 KRAS degrader-1 (compound 1) is a potent KRAS degrader.
ORM-5029 V88375 ORM-5029 ORM-5029 is the first antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), which is a combination of the highly effective GSPT1 degrader SMol006 and Pertuzumab.
Raludotatug Deruxtecan V94455 Raludotatug Deruxtecan Raludotatug Deruxtecan (DS-6000) is a novel antibody-drug conjugate (ADC) targeting CDH6.
SGN-B6A V104025 SGN-B6A SGN-B6A is an ADC that targets integrin β-6 (ITGB6) via the human IgG1 monoclonal antibody Sigvotatug and exhibits cytotoxicity against a variety of integrin β-6-positive cancer cells via the mitotic inhibitor MMAE.
SMP-33693 V81404 SMP-33693 SMP-33693 is an Antibody-Drug Conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer.
SMP-88480 V81405 SMP-88480 SMP-88480 is an Antibody-Drug Conjugates (ADCs).
SMP-93566 V81406 SMP-93566 SMP-93566 is an Antibody-Drug Conjugates (ADCs) with a low payload shedding rate and has in vivo tumor suppressive effects on ovarian cancer, gastric cancer, and breast cancer.
Contact Us